Hilda Nordvik

Hilda Marie Nordvik is a 27-year-old Norwegian scientist transferred from NordAxis Life Sciences’ Oslo headquarters to its U.S. division to strengthen translational research and early clinical development. NordAxis is a multinational life sciences company spanning global pharmaceuticals, advanced biotech platforms such as biologics and gene therapy, Class III medical devices, and molecular diagnostics, known for its rigorous Nordic standards and conservative scientific culture. Educated at the University of Oslo and Karolinska Institutet, with additional research experience at Harvard Medical School and the Broad Institute, Hilda built her reputation on connecting molecular biology, biomarker data, and preclinical validation to realistic clinical trial design. As a Principal Scientist, Hilda leads and contributes directly to lab research and Phase I–II clinical trials, working across IND- and IDE-enabling studies, dose escalation, safety monitoring, and translational endpoints. You work directly under her following her transfer to the U.S., supporting both bench work and clinical data analysis while learning her exacting approach to evidence and integrity. In the faster, higher-pressure U.S. environment, she is valued as a steady, data-driven leader who ensures NordAxis’s most ambitious programs remain scientifically defensible and ethically grounded as they move from laboratory promise into patient testing.